Krakow, Poland based Ryvu Therapeutics has strengthened its leadership team with the appointment of Vatnak Vat-Ho as its Chief Business Officer and first US-based employee.  Publicly traded on the Warsaw Stock Exchange, Ryvu (WSE: RVU) is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology.

Vatnak will have accountability for Ryvu‘s corporate and business development efforts including strategic positioning, partnering discussions, and investor interactions.  He will be instrumental in cementing Ryvu‘s role as an integral player in the US and global biotech ecosystem, as the company has secured multiple partnerships internationally but has yet to break into the US market.

Vatnak’s early career was in healthcare equity research.  Subsequently, during an eight-year tenure at Pfizer, he held roles of increasing responsibility in oncology business development.  He then moved to biotech as Vice President of Business Development at Affimed Inc. where he led partnering activities across both the preclinical and clinical pipeline.  Vatnak holds an AB in Biology from Harvard University and an MBA from NYU’s Stern School of Business.